| Literature DB >> 24206944 |
Avigyle Grunbaum, Christina Holcroft, Debra Heilpern, Stephanie Gladman, Barry Burstein, Maryse Menard, Jasim Al-Abbad, Jamie Cassoff, Elizabeth MacNamara, Philip H Gordon, Andrew Szilagyi1.
Abstract
BACKGROUND: 25(OH) vitamin D levels may be low in patients with moderately or severely active inflammatory bowel diseases (IBD: Crohn's disease and Idiopathic Ulcerative Colitis) but this is less clear in patients with mild or inactive IBD. Furthermore there is limited information of any family influence on 25(OH) vitamin D levels in IBD. As a possible risk factor we hypothesize that vitamin D levels may also be low in families of IBD patients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24206944 PMCID: PMC3828424 DOI: 10.1186/1475-2891-12-145
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Demographics Counts (%) are reported unless otherwise noted
| 39.9 ± 12.3 yr | 44.2 ± 13.7 yr | 46.5 ± 21.6 yr | 39.6 ± 13.8 yr | 30.5 ± 18.7 yr | ||
| 21 (61.8%) | 13 (61.9%) | 42 (76.4%) | 38 (79.2%) | 30 (62.5%) | ||
| 24.2 ± 4.1 kg/m2 | 25.4 ± 3.2 kg/m2 | 24.6 ± 4.6 kg/m2 | 25.7 ± 7.9 kg/m2 | 24.9 ± 6.5 kg/m2 | ||
| Caucasian* | 32 (94.1%) | 20 (95.2%) | 51 (92.7%) | 38 (79.2%) | 38 (79.2%) | |
| Jewish | 15 (44.1%) | 13 (61.9%) | 29 (52.7%) | 20 (41.6%) | 20 (41.6%) | |
| Sunny: May - Sept | 15 (44.1%) | 10 (47.6%) | 28 (50.9%) | 21 (43.8%) | 22 (45.8%) | |
| Less Sunny: Oct. - Apr | 19 (55.9%) | 11 (52.3%) | 27 (49.1%) | 27 (56.3%) | 26 (54.2%) | |
| 3 (8.8%) | 3 (14.3) | 5 (9.1%)^ | 6 (12.5)% | 2 (4.2)% | ||
| 0 | 1 (4.8%) | 0 | 1 (2.1)% | 1 (2.1)% | ||
| 4 (11.8%) | 0 | 3 (5.5)% | 4 (8.3%) | 1 (2.1)% | ||
| 2.6 ± 1.9 (20.6% mild active) | 2 ± 1.3 (0% active) | | | | ||
| 85.6 ± 140.2 month | 39.7 ± 53.5 month | | | | ||
| Colon | 13 (38.2%) | Pan Colitis: 16 (76.2%) | | | | |
| Ileo-colon | 12 (35.3%) | Left limit: 4 (19%) | | | | |
| Small bowel | 9 (26.6%) | Unclear: 1 (5%) | | | | |
| 5ASA | 6 (17.7%) | 17 (81%) | | 0 | 1 diagnosed with leukemia | |
| Corticosteroids | 4 (11.8%) | 4 (19%) | ||||
| Immunomodulators | 5 (14.7%) | N1 (4.8%) | ||||
| Biologics | 3 (8.8%) | 3 (14.3%) | ||||
| Colon | 0 | Colectomy: 1 (4.8%) | | | | |
| Colon and/or Small Bowel | 11 (32.4%) | | | | | |
| Ileostomy | 3 (8.8%) | |||||
* Chi-square comparison of Caucasian in Patient vs. Controls yields p = 0.019.
^ Missing information on participants ranged from 25-50%.
** Score for Crohn’s based on Harvey Bradshaw Index [34] Inactive ≤ 4.
Score for Ulcerative Colitis based on Simple Clinical Colitis activity Index [35]. Inactive < 4.
Serum 25[OH] vitamin D by Groups
| IBD Patients | 71.2 ± 32.8** | 21 (38.2%) | 12 (21.8%) | 17 (30.9%) |
| 15(71.4%) | 3 (25%) | 8 (47.1%) | ||
| Crohn’s Disease | 71.1 ± 31.1 | 14 (41.2%) | 7 (20.6%) | 10 (29.4%) |
| 9 (64.3%) | 2 (28.6%) | 5 (50%) | ||
| Ulcerative Colitis | 71.4 ± 36.3 | 7 (33.3%) | 5 (23.8%) | 7 (33.3%) |
| 6 (85.7%) | 1 (20%) | 3 (42.9%) | ||
| Patients’ Family | 82.3 ± 34.2 | 27 (49.1%) | 18 (32.7%) | 7 (12.7%) |
| 13 (48.2%) | 5 (27.8%) | 1 (14.3%) | ||
| Healthy Control | 68.3 ± 26.2 | 15 (31.3%) | 19 (39.6%) | 11 (22.9%) |
| 7 (46.7%) | 11 (57.9%) | 4 (36.4%) | ||
| Controls’ Family | 69.9 ± 27.6 | 19 (39.6%) | 16 (33.3%) | 11 (22.9%) |
| 8 (88.9%) | 5 (31.3%) | 1 (9.1%) |
Levels and categories of serum 25[OH] vitamin D in nmol/L overall and by patient, control and their respective families are shown. The lower values represent the number of participants in each category who consumed supplemental vitamin D and the percentage of the category in each group. Based on (n = 193) available serum levels.
* Because of some missing data on serum 25[OH] vitamin D levels, percentages do not sum to 100%. Missing data were as follows:
5 from IBD.
3 from Family IBD.
3 from Control.
2 from Family Control.
** patient vs. family: p = 0.0332 (paired t test) or p = 0.0164 (for log values).
Intake of total, dietary or supplemental vitamin D and calcium by groups
| 54 | 54 | 46 | 48 | |
| Mean ± SD IU | 371 ± 333 | 527 ± 803 | 600 ± 848 | 666 ± 592 |
| Median | 286 | 260 | 394 | 416 |
| 54 | 54 | 46 | 48 | |
| Mean ± SD | 784.4 ± 720 | 761.3 ± 881.6 | 917 ± 1028 | 867 ± 801 |
| Median | 599.5 | 523 | 590.2 | 612. |
| 29 | 20 | 23 | 15 | |
| Mean ± SD | 1110 ± 780* | 1116.2 ± 809.7** | 1279 ± 857** | 1344.9 ± 994.2** |
| Median | 932.4 | 932.8 | 1020.8 | 1191.1 |
| 23 | 34 | 23 | 32 | |
| Mean ± SD | 404.2 ± 409.2 | 552.5 ± 865.8 | 554.3 ± 1074.4 | 648.4 ± 605.3 |
| Median | 332.8 | 291.7 | 290.4 | 377.4 |
| 54 | 54 | 46 | 48 | |
| Mean ± SD | 1537.2 ± 755 | 1687.4 ± 1071.5 | 1778.7 ± 1127.2 | 1931.4 ± 1325.6 |
| Median | 1479 | 1404.7 | 1552.1 | 1679.5 |
Vitamin D intake is listed in International Units (conversion to μg is IU/40). Total daily calcium is listed as g/day. Vitamin D intakes were skewed and therefore both mean ± standard deviation and median values are listed. N values for each group represents original number in the groups and n values actual numbers analyzed.
Comparisons of means of groups with and without vitamin D supplements were significant; * p < 0.01, ** p < 0.05.
Serum 25[OH] vitamin D according to intakes of vitamin D
| 26 | 19 | 22 | 14 | |
| Mean ± SD | 79.8 ± 36.5* | 86.7 ± 24.1 | 70.2 ± 26.5 | 74.6 ± 15.9 |
| 21 | 32 | 22 | 31 | |
| Mean ± SD | 59.4 ± 25.0 | 79.9 ± 39.6 | 67.9 ± 26.1 | 68.2 ± 31.8 |
| | | | | |
| May-Sept, n | 23 | 27 | 19 | 21 |
| Mean ± SD | 81.6 ± 32.5 ** | 83.7 ± 32.1 | 69.5 ± 26.3 | 73.3 ± 30.9 |
| Oct-April, n | 27 | 25 | 26 | 25 |
| Mean ± SD | 62.4 ± 31.0 | 80.8 ± 36.9 | 67.4 ± 26.6 | 67.1 ± 24.7 |
The effects of vitamin D intake on 25[OH] vitamin D with or without supplement or seasons of testing are shown for four groups. All serum 25[OH] vitamin D levels are reported as nmol/L. May –Sept are sunny months, October –April are non sunny months. N values for each group represents original number in the groups and n values actual numbers analyzed.
* The comparison of means ± SD was significant (p = 0.03 compared with patients not taking vitamin D supplements). However comparing log 25[OH] vitamin D the result became nonsignifcant (p = 0.059).
** p = 0.039 compared with patients evaluated in October to April.
Figure 125[OH] vitamin D levels and the effect of intake in groups by seasons. a. Winter: Patients (N 26) (r2 = 0.315, r = 0.561, p = 0.003), Families of patients (N25) (r2 < 0.001, r = 0.003, p = 0.990), Controls (N26) (r2 = 0.129, r = 0.359, p = 0.072) and Families of controls (N25) (r2 < 0.001, r = 0.010, p = 0.961). b. Summer: Patients (N = 23): (r2 = 0.036, r = 0.191, p = 0.384), Families of patients (N26): (r2 = 0.024, r = -0.156, p = 0.448), Controls (N18): (r2 = 0.018, r = -0.134, p = 0.597) and Families of controls (N21): (r2 = 0.092, r = 0.303, p = 0.182).
Figure 2Relationships of serum 25[OH] vitamin D levels within families by seasons. a. Correlations, slopes and p-values for plots of log serum VitD-25 of Patients vs. Families of patients in Summer (N22) (r2 = 0.2098, r = 0.458, p = 0.032): b winter (N22) (r2 = 0.0672, r = 0.259, p = 0.24), c Controls vs. Families of controls in summer (N18) (r2 = 0.1969, r = 0.444, p = 0.065), d in winter (N25) (r2 = 0.0068, r = 0.082, p = 0.6955).